Compare Aventis Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs PANACEA BIOTECH - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA PANACEA BIOTECH SANOFI INDIA/
PANACEA BIOTECH
 
P/E (TTM) x 34.8 11.3 309.6% View Chart
P/BV x 6.1 2.7 225.7% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 SANOFI INDIA   PANACEA BIOTECH
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
PANACEA BIOTECH
Mar-18
SANOFI INDIA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs6,840364 1,879.1%   
Low Rs4,630129 3,586.4%   
Sales per share (Unadj.) Rs1,203.196.8 1,243.1%  
Earnings per share (Unadj.) Rs165.3-12.4 -1,331.9%  
Cash flow per share (Unadj.) Rs209.9-2.9 -7,357.6%  
Dividends per share (Unadj.) Rs84.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs963.650.4 1,912.0%  
Shares outstanding (eoy) m23.0361.25 37.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.82.5 187.1%   
Avg P/E ratio x34.7-19.9 -174.6%  
P/CF ratio (eoy) x27.3-86.4 -31.6%  
Price / Book Value ratio x6.04.9 121.7%  
Dividend payout %50.80-   
Avg Mkt Cap Rs m132,07815,101 874.6%   
No. of employees `0003.32.5 133.8%   
Total wages/salary Rs m4,0681,516 268.4%   
Avg. sales/employee Rs Th8,393.82,401.9 349.5%   
Avg. wages/employee Rs Th1,232.4614.2 200.6%   
Avg. net profit/employee Rs Th1,153.0-307.9 -374.4%   
INCOME DATA
Net Sales Rs m27,7085,928 467.4%  
Other income Rs m89782 1,089.9%   
Total revenues Rs m28,6056,010 475.9%   
Gross profit Rs m6,235845 737.6%  
Depreciation Rs m1,027585 175.5%   
Interest Rs m71,006 0.7%   
Profit before tax Rs m6,098-664 -919.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,29299 2,324.5%   
Profit after tax Rs m3,806-760 -500.8%  
Gross profit margin %22.514.3 157.8%  
Effective tax rate %37.6-14.9 -252.9%   
Net profit margin %13.7-12.8 -107.1%  
BALANCE SHEET DATA
Current assets Rs m15,9225,603 284.1%   
Current liabilities Rs m6,2356,910 90.2%   
Net working cap to sales %35.0-22.0 -158.6%  
Current ratio x2.60.8 314.9%  
Inventory Days Days64206 30.9%  
Debtors Days Days2184 24.9%  
Net fixed assets Rs m7,5399,941 75.8%   
Share capital Rs m23061 375.2%   
"Free" reserves Rs m21,9623,026 725.9%   
Net worth Rs m22,1923,087 718.9%   
Long term debt Rs m05,707 0.0%   
Total assets Rs m29,83916,076 185.6%  
Interest coverage x872.10.3 256,266.8%   
Debt to equity ratio x01.8 0.0%  
Sales to assets ratio x0.90.4 251.8%   
Return on assets %12.81.5 835.7%  
Return on equity %17.2-24.6 -69.7%  
Return on capital %27.53.9 702.4%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m7,5871,600 474.2%   
Fx outflow Rs m7,1451,131 631.5%   
Net fx Rs m442469 94.3%   
CASH FLOW
From Operations Rs m3,7391,180 316.8%  
From Investments Rs m-731553 -132.2%  
From Financial Activity Rs m-1,972-1,644 120.0%  
Net Cashflow Rs m1,03690 1,155.0%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 0.6 2,400.0%  
FIIs % 14.6 1.3 1,123.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 23.6 44.5%  
Shareholders   15,184 10,259 148.0%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare SANOFI INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Oct 14, 2019 02:17 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS